• Consensus Rating: Buy
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.58
▼ -0.01 (-1.70%)

This chart shows the closing price for DRRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New DURECT Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DRRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DRRX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for DURECT in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.58.

This chart shows the closing price for DRRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in DURECT. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/9/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/8/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/6/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/4/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/3/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/1/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/3/2021Cantor FitzgeraldReiterated RatingOverweightLow
5/5/2021HC WainwrightReiterated RatingBuy$6.00High
2/3/2021Chardan CapitalBoost TargetBuy$7.00 ➝ $8.00High
11/26/2020Chardan CapitalReiterated RatingBuy$7.00Low
10/30/2020Chardan CapitalInitiated CoverageBuy$7.00Medium
10/12/2020Roth CapitalInitiated CoverageBuy$7.00Low
10/9/2020Cantor FitzgeraldReiterated RatingOverweightMedium
7/30/2020OppenheimerInitiated CoverageOutperform$7.00High
6/29/2020B. RileyReiterated RatingBuy$5.00High
5/27/2020HC WainwrightBoost TargetBuy$5.50 ➝ $6.00High
5/26/2020B. RileyReiterated RatingBuy$5.00Medium
5/12/2020B. RileyReiterated RatingBuy$5.00High
5/12/2020HC WainwrightReiterated RatingBuy$5.50Medium
3/4/2020B. RileyReiterated RatingBuy$5.00High
1/31/2020B. RileyInitiated CoverageBuy$5.00Medium
1/22/2020Craig HallumInitiated CoverageBuyMedium
1/3/2020HC WainwrightReiterated RatingBuy$5.50High
11/18/2019Cantor FitzgeraldInitiated CoverageBuy$5.00Low
10/17/2019Cantor FitzgeraldReiterated RatingOverweightHigh
9/18/2019HC WainwrightSet TargetBuy$3.50Low
9/18/2019Stifel NicolausBoost TargetHold$1.50 ➝ $2.10Low
9/10/2019HC WainwrightReiterated RatingBuy$3.50High
9/6/2019Cantor FitzgeraldInitiated CoverageOverweight$5.00High
7/19/2019HC WainwrightSet TargetBuy$4.00Low
5/9/2019HC WainwrightReiterated RatingBuy$3.50Medium
4/18/2019HC WainwrightReiterated RatingBuyMedium
1/7/2019HC WainwrightReiterated RatingBuy$3.00High
7/31/2018HC WainwrightReiterated RatingBuy$3.00High
3/6/2018HC WainwrightUpgradeNeutral ➝ Buy$1.50 ➝ $3.50High
11/2/2017HC WainwrightReiterated RatingHoldN/A
10/20/2017LaidlawLower TargetBuy ➝ Buy$3.00 ➝ $2.00N/A
10/20/2017HC WainwrightDowngradeBuy ➝ Neutral$3.00N/A
10/20/2017Stifel NicolausDowngradeBuy ➝ HoldN/A
(Data available from 10/1/2017 forward)

News Sentiment Rating

-0.05 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
3/5/2022
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/4/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/4/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
6/3/2022
  • 4 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/3/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/2/2022
  • 1 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
9/1/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/1/2022

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
DURECT logo
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.
Read More

Today's Range

Now: $0.58
Low: $0.55
High: $0.61

50 Day Range

MA: $0.66
Low: $0.43
High: $0.91

52 Week Range

Now: $0.58
Low: $0.36
High: $1.34

Volume

279,009 shs

Average Volume

242,887 shs

Market Capitalization

$131.69 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.21

Frequently Asked Questions

What sell-side analysts currently cover shares of DURECT?

The following equities research analysts have issued reports on DURECT in the last twelve months: Cantor Fitzgerald, and StockNews.com.
View the latest analyst ratings for DRRX.

What is the current price target for DURECT?

0 Wall Street analysts have set twelve-month price targets for DURECT in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for DURECT in the next year.
View the latest price targets for DRRX.

What is the current consensus analyst rating for DURECT?

DURECT currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DRRX will outperform the market and that investors should add to their positions of DURECT.
View the latest ratings for DRRX.

What other companies compete with DURECT?

How do I contact DURECT's investor relations team?

DURECT's physical mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The specialty pharmaceutical company's listed phone number is (408) 777-1417 and its investor relations email address is [email protected] The official website for DURECT is www.durect.com. Learn More about contacing DURECT investor relations.